A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib

被引：0

作者：

David Proudman

Dave Nellesen

Deepshekhar Gupta

Deyaa Adib

Jay Yang

Khalid Mamlouk

机构：

[1] Analysis Group,

[2] Inc.,undefined

[3] Epizyme,undefined

[4] Inc.,undefined

来源：

Advances in Therapy | 2022年 / 39卷

关键词：

Aliqopa; Anticancer agents; Copiktra; Relapsed/refractory follicular lymphoma; Tazverik; Ukoniq; Zydelig;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1678 / 1696

页数：18

共 64 条

[41]

Gopal AK(undefined)undefined undefined undefined undefined-undefined

[42]

Kahl BS(undefined)undefined undefined undefined undefined-undefined

[43]

Flowers CR(undefined)undefined undefined undefined undefined-undefined

[44]

Okosun J(undefined)undefined undefined undefined undefined-undefined

[45]

Bödör C(undefined)undefined undefined undefined undefined-undefined

[46]

Batlevi C(undefined)undefined undefined undefined undefined-undefined

[47]

Cheson BD(undefined)undefined undefined undefined undefined-undefined

[48]

Pfistner B(undefined)undefined undefined undefined undefined-undefined

[49]

Juweid ME(undefined)undefined undefined undefined undefined-undefined

[50]

Cheson BD(undefined)undefined undefined undefined undefined-undefined